BioSpace News Archive

June 19, 2019 13:54 UTC New Oat Variety Marked by High Yield, Disease Resistance MINNEAPOLIS & ST. PAUL, Minn.--( BUSINESS WIRE )-- The University of Minnesota (UMN), in collaboration with the University of Saskatchewan, has released a new white hull oat variety called ‘MN-Pearl.’ MN-Pearl is a high-yielding variety with good straw strength and high groat percentage. It also has good overall disease resistance in

The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more research organizations, including the first in Jordan.

Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer

CipherHealth, the leading patient engagement software company, is gathering the brightest minds in healthcare for its “Partners in Excellence Conference 2019" in San Diego June 19th - 20th to discuss proven strategies in achieving superior engagement and coordination throughout the care continuum.

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company’s ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab

A new study performed in conjunction with the Harvey L. Neiman Health Policy Institute examines changing characteristics of utilization and potential disparities in US emergency department (ED) patients undergoing CT of the abdomen and pelvis (CTAP) for suspected urolithiasis.

Since the China launch earlier this year of an immuno-oncology drug at one-third the price of Merck’s Keytruda, there has been a wave of applications for affordable innovative therapies from China, developed to Western standards of safety and efficacy, to register in the US.

Health systems continue to invest significant time and resources in designing, negotiating and implementing various types of partnerships and affiliations.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Tracleer®1 (bosentan) tablets, 62.5 mg and 125 mg, in the U.S.

The Silicon Valley Business Journal named Tivic Health Systems’ Chief Scientific Officer, Blake Gurfein, PhD to their annual 40 Under 40 Awards which honors 40 business executives, entrepreneurs, nonprofit leaders and community officials who have made an indelible mark before they reached the age of 40.